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Background
VRC01, a broadly neutralizing monoclonal antibody
(bnmAbs), is capable of neutralizing a diverse array of
HIV-1 isolates through recognition of the loop D and the
V5 regions within the CD4 binding site on envelope glyco-
protein gp120. Nonetheless, resistant strains have been
identified. Here, we examined two closely related envelope
clones derived at a single time point from a CRF08_BC
infected patient which displayed an over 20-fold difference
in VRC01 neutralization sensitivity.
Methods
A total of 15 chimeric envelope clones were generated by
interchanging the loop D and/or V5 regions between the
original envelopes or by single alanine substitutions within
each region. The resultant effects on VRC01 neutralization
sensitivity were subsequently studied in the context of
pseudotyped viruses.
Results
Our results showed that interchanging the V5 region
between the two clones completely swapped their neutrali-
zation sensitivity profiles, while exchanging the loop D
region alone had minimal impact. Mutagenesis analysis
revealed that the potential N-linked glycosylation site
(PNGS) at position 460 in the V5 region contributed to
over 90% of observed resistance, while other amino acid
changes made no discernible differences. Furthermore,
changes in resistance were found to positively correlate
with VRC01 binding activity to the corresponding envel-
ope glycoprotein. None of the substitutions, however, sig-
nificantly altered binding and neutralization sensitivity to
bnmAb b12 or soluble CD4. Of note, a mutation that
removed the PNGS at position 463 in the V5 region
increased resistance to ibalizumab, a non-immunosuppres-
sive monoclonal antibody that binds CD4 and has been
shown to inhibit entry of diverse HIV-1 isolates.
Conclusion
In summary, our data indicates that amino acid residues in
the V5 region play a critical role in determining viral sensi-
tivity to VRC01. Increased length, glycosylation and long
side-chain of amino acids in the V5 region may collectively
create steric hindrance that lowers binding affinity, thereby
increasing resistance to VRC01 neutralization.
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